The phase III KEYNOTE-671 trial investigating Keytruda, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage 2, 3A or 3B non-small cell lung cancer met its dual primary endpoint of overall survival.
FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
